Sagimet Biosciences (SGMT) Set to Post Earnings on Thursday

Sagimet Biosciences (NASDAQ:SGMT) is expected to announce its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Sagimet Biosciences to announce earnings of ($0.25) per share and revenue of $0.17 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). On average, analysts expect Sagimet Biosciences to post ($1.14) EPS for the current fiscal year and ($1.06) EPS for the next fiscal year.

Sagimet Biosciences Price Performance

SGMT opened at $10.83 on Tuesday. The firm has a market capitalization of $673.19 million, a PE ratio of -8.46 and a beta of 3.43. The business’s 50-day moving average is $9.86 and its two-hundred day moving average is $7.59. Sagimet Biosciences has a 1 year low of $4.50 and a 1 year high of $11.45.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Guggenheim boosted their price objective on shares of Sagimet Biosciences from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Sagimet Biosciences in a research report on Monday, October 5th. Oppenheimer raised their target price on shares of Sagimet Biosciences from $33.00 to $38.00 and gave the company an “outperform” rating in a research note on Thursday, October 1st. Finally, Citigroup restated a “market outperform” rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.63.

Sagimet Biosciences Company Profile

Sagimet Biosciences, Inc (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing therapies that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company is focused on using FASN inhibition to address metabolic, inflammatory and oncological diseases for which additional treatment options are needed.

Sagimet’s lead investigational product is denifanstat, an orally administered, selective FASN inhibitor formerly known as TVB-2640. The company has primarily advanced denifanstat as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease associated with liver inflammation and fibrosis.